ArticleScientific reports2024
Characteristics of the extended-spectrum-β-lactamase-producing Escherichia coli isolated from diseased livestock and poultry in Taiwan.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Prevalence, genomic characterization, and biofilm-forming capacity of extended-spectrum β-lactamase-producing Escherichia coli from faecal samples of broiler chickens in Jinan City, China.Poultry science · 2026Article
- Genomic Characterization of Colistin and Fluoroquinolone Resistance in Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Influence of housing system on antimicrobial resistance and population structure of extended-spectrum beta-lactamase-producing Escherichia coli in South Korean layer farms.Poultry science · 2026Article
- Emergence of multidrug-resistant and virulent Escherichia coli with APEC‑associated traits in broiler chickens from Ismailia, Egypt.Scientific reports · 2026Article
- Cross-sectoral sharing of CTX-M-producingMicrobiology spectrum · 2026Article
- Article
- Fluoroquinolone resistance without fluoroquinolone use; the genie is truly out of the bottle.Frontiers in microbiology · 2026Review
- Evaluation ofFrontiers in veterinary science · 2026Article
- Genotypic Characterization of Virulence Factors in Extended-Spectrum Beta-Lactamase (ESBL)-ProducingAntibiotics (Basel, Switzerland) · 2025Article
- Phenotypic and Molecular Study of Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Oral and parenteral treatment with a third-generation cephalosporin promotes the proliferation of diverse ESBL-producingmSphere · 2025Article
- Phenotypic and Genotypic Characterization of ESBL andAntibiotics (Basel, Switzerland) · 2025Article
- Public health threat of antimicrobial resistance and virulence genes in Escherichia coli from human-chicken transmission in Egypt.Scientific reports · 2025Article
- Comprehensive regional study of ESBLFrontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
A total of 297 Escherichia coli isolates from diseased livestock with diarrhea and 269 isolates from poultry affected by colibacillosis were assessed for extended-spectrum-β-lactamase (ESBL) production. In livestock, 36 isolates (12.1%) were ESBL-producing, with pigs (52.8%), cattle (30.5%), and goats (16.7%) being the most affected. Poultry exhibited 22 ESBL-producing strains (8.6%), with distribution among species: chicken (36.3%), duck (22.7%), goose (22.7%), and others (18.2%). ESBL-producing E. coli demonstrated higher drug resistance, except for amoxicillin/clavulanic acid, while all isolates were susceptible to imipenem. The bla
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.